The study mentions that PTGS2 is a marker of CRC progression [134]; therefore, decreased ELK1 expression could be a marker for an advanced stage disease, as has also been demonstrated by other researchers [133]. This evidence concerns the gene ELK1 and colorectal carcinoma.